Detalhe da pesquisa
1.
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
J Infect Dis
; 215(1): 95-104, 2017 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28077588
2.
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Ann Intern Med
; 164(5): 313-22, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26833336
3.
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.
NPJ Vaccines
; 9(1): 58, 2024 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467663
4.
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
Sci Transl Med
; 15(697): eadf3309, 2023 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37224227
5.
Ultrasound-guided lymph node fine-needle aspiration for evaluating post-vaccination germinal center responses in humans.
STAR Protoc
; 4(4): 102576, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733596
6.
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.
medRxiv
; 2023 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36993183
7.
Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
J Virol
; 83(14): 7337-48, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19439467